- Home
- RLTY vs SERA Comparison
RLTY vs SERA Comparison
Compare RLTY & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLTY
- SERA
- Stock Information
- Founded
- RLTY 2022
- SERA 2008
- Country
- RLTY United States
- SERA United States
- Employees
- RLTY N/A
- SERA N/A
- Industry
- RLTY Investment Managers
- SERA Precision Instruments
- Sector
- RLTY Finance
- SERA Health Care
- Exchange
- RLTY Nasdaq
- SERA Nasdaq
- Market Cap
- RLTY 251.8M
- SERA 70.4M
- IPO Year
- RLTY N/A
- SERA 2021
- Fundamental
- Price
- RLTY $15.49
- SERA $2.49
- Analyst Decision
- RLTY
- SERA
- Analyst Count
- RLTY 0
- SERA 0
- Target Price
- RLTY N/A
- SERA N/A
- AVG Volume (30 Days)
- RLTY 86.7K
- SERA 806.3K
- Earning Date
- RLTY 01-01-0001
- SERA 08-06-2025
- Dividend Yield
- RLTY 9.35%
- SERA N/A
- EPS Growth
- RLTY N/A
- SERA N/A
- EPS
- RLTY N/A
- SERA N/A
- Revenue
- RLTY N/A
- SERA $115,000.00
- Revenue This Year
- RLTY N/A
- SERA $390.13
- Revenue Next Year
- RLTY N/A
- SERA $440.54
- P/E Ratio
- RLTY N/A
- SERA N/A
- Revenue Growth
- RLTY N/A
- SERA N/A
- 52 Week Low
- RLTY $11.38
- SERA $1.37
- 52 Week High
- RLTY $14.60
- SERA $9.13
- Technical
- Relative Strength Index (RSI)
- RLTY 61.96
- SERA 53.89
- Support Level
- RLTY $15.00
- SERA $1.82
- Resistance Level
- RLTY $15.49
- SERA $4.09
- Average True Range (ATR)
- RLTY 0.23
- SERA 0.36
- MACD
- RLTY 0.03
- SERA 0.10
- Stochastic Oscillator
- RLTY 92.31
- SERA 35.74
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.